Inside Precision Medicine November 2, 2022
Chris Anderson

Myriad Genetics announced on Tuesday that it acquired consumer-focused prenatal and pediatric genomic test developer Gateway Genomics for $67.5 million in cash. The deal could pay Gateway an additional an additional $32.5 million of cash payments in 2023 and 2024 if certain revenue, volume synergy and EBITDA targets are achieved.

Via the Gateway acquisition, Myriad adds the SneakPeek Early Gender DNA test to its portfolio of women’s health products. According to the companies, SneakPeek is the top selling at-home gender test for expectant families and can deliver results with 99% accuracy only six weeks into the term of a pregnancy. Other products in Myriad’s women’s health line include the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with...

Today's Sponsors

Zelis
HealthITq
Premier

Today's Sponsors

Upfront Healthcare
pCare

Today's Sponsor

Curation Health

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Merck to buy blood cancer biotech Imago for $1.35B
Arcturus and CSL Seqirus Ink Deal on mRNA-Based Infectious Disease Vaccines
AstraZeneca to acquire DNA medicine company
AstraZeneca to acquire gene editing biotech LogicBio
Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred